Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both ketoconazole 2% shampoo and selenium sulphide are effective for dandruff treatment, but ketoconazole also reduces hair growth.

This report discusses the use of intralesional cidofovir and suggests it might be a viable option for treating SCC due to its successful outcome without observed systemic toxicity in this case.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This study using a genetic mouse model found that S. aureus-driven dysbiosis sustains inflammatory skin side effects from EGFR inhibitors, suggesting prophylactic antibiotic treatment may reduce rash severity without fixing barrier defects.

This article reviews acute and prophylactic treatments for cluster headaches, highlighting sumatriptan injections, oxygen therapy, and verapamil as effective options, but reports no new clinical results.

In this study, topical 2% minoxidil did not significantly improve hair density measures in men with male pattern baldness, although there was no deterioration, suggesting a potential prophylactic effect.

Genetic testing for cancer risk can lead to early and life-saving treatments in people without symptoms.

Topical minoxidil may slow hair loss but often doesn't lead to satisfactory hair regrowth and requires ongoing treatment.

In this study, PTH-CBD effectively prevented and partially reversed chemotherapy-induced alopecia in mice, with pretreatment offering a better cosmetic outcome compared to therapeutic administration after hair loss onset.

This study concluded that Metformin may be suitable for prophylaxis or mild COVID-19, while a combination of Oseltamivir, Tamoxifen, and Dexamethasone could benefit moderate to severe cases, highlighting the need for more trials on other drug candidates.

In this study, two-thirds of patients with persistent chronic daily headache significantly improved with divalproex sodium treatment, while liver functions remained unaffected.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

In this review, the authors summarize classical and recent insights into the biology and treatment of hypertrophic scars and keloids, concluding that while understanding and strategies have advanced, effective prevention and treatments remain unsatisfactory.

This article provides a narrative on managing dermatologic side effects from cancer therapies and suggests strategies that oncologists could adopt, but it reports no new clinical findings.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

In this study, prophylactic treatment with a neutralizing monoclonal antibody against α-toxin reduced wound sizes and bacterial burden while enhancing healing in both non-diabetic and diabetic mice with S. aureus skin infections.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

This systematic review reports that prophylactic minocycline and pyridoxine may reduce certain skin toxicities in cancer patients, but evidence quality for various interventions was limited and future research is needed.

This review discusses the developments in antifungal treatments for dermatophyte infections since 2008, reporting no new oral agents but introducing newer topical options like efinaconazole and tavaborole.

This study found that two-thirds of patients with persistent chronic daily headache showed significant improvement with divalproex sodium treatment, although common side effects included weight gain, tremor, hair loss, and nausea.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.